A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis. The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) Total Score.

NCT Number	NCT07038876
Lead Sponsor	MapLight Therapeutics
Conditions	Schizophrenia
Enrollment	307 participants
Start Date	2025-06-27
Primary Completion	2026-06-04 (estimated)
Study Completion	2026-06-11 (estimated)
Updated on ClinicalTrials.gov	2026-07-09